Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$CYTK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.50 down -33.93% YoY • Reported revenue of $28.62M down -57.13% YoY • Cytokinetics is updating its full year 2026 financial guidance for GAAP combined R&D and SG&A expense to $860 million to $890 million, including $140 million to $130 million of stock-based compensation.

Price since post

Full Details

Advertisement|Remove ads.